- Roche and KlinRisk received CE-mark for AI-based CKD risk tool.
- CKD affects over 700 million globally, linked to diabetes and hypertension.
- The CKD panel is available in Europe and UK, with later launches in US, Middle East, and Asia.
- The navify platform integrates with hospital systems for seamless access.
AI-Based CKD Risk Tool
Roche, in collaboration with KlinRisk, has received CE-mark approval for an AI-based risk stratification tool designed to assess the progressive decline in kidney function. This tool is part of Roche's new Chronic Kidney Disease (CKD) algorithm panel, aimed at supporting care across all stages of the disease.
Global Health Challenge
Chronic kidney disease affects over 700 million people worldwide and is recognized as a significant public health challenge. Early diagnosis and treatment can delay or prevent kidney function decline, reduce cardiovascular risk, and lower healthcare costs.
Comprehensive Risk Assessment
The CKD panel includes the Kidney Klinrisk Algorithm for early risk assessment and the established Kidney KFRE Algorithm for managing later stages of CKD. It provides clinicians with a comprehensive risk assessment solution, integrating multiple input factors from routine tests and aligning with clinical guidelines.
Availability and Integration
The CKD algorithm panel is available on Roche's navify® Algorithm Suite, a cloud-based platform that integrates with existing hospital systems. It is currently available in Europe and the UK, with plans for later launches in the United States, the Middle East, and Asia.
Addressing Rising Incidence
The rising incidence of CKD is driven by increasing cases of diabetes, hypertension, and obesity. CKD can lead to increased hospitalizations, cardiovascular disease, and early mortality, making adherence to guideline-directed medical therapies crucial.
